Peter Jenson, MD
Family Medicine · Fallbrook, CANPI 1184835407
Payments from drug & device makers
Across 103 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$558
- GSK$287
- Shire North American Group Inc$150
- AbbVie$142
- Pfizer$128
- Lilly USA, LLC$93
- plus $715 from 21 others
What the payments were for
- Food & beverage$2,03498%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $558 |
| GSK | 14 | $287 |
| Shire North American Group Inc | 2 | $150 |
| AbbVie(2 entities) | 6 | $142 |
| Pfizer | 8 | $128 |
| Lilly USA, LLC | 4 | $93 |
| Astellas Pharma US Inc | 5 | $89 |
| Novartis | 3 | $68 |
| Merck | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Amgen | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Cranial Technologies, Inc | 3 | $44 |
| Qiagen, LLC | 1 | $32 |
| Bayer | 2 | $32 |
| Boston Scientific | 1 | $27 |
| Mannkind Corporation | 2 | $26 |
| Novo Nordisk | 2 | $23 |
| Abbott | 1 | $23 |
| IBSA Pharma Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| BD | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
How this compares
$2,074 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 235 | $146,510 |
| XareltoRivaroxaban | 59 | $57,057 |
| OzempicSemaglutide | 54 | $56,623 |
| JardianceEmpagliflozin | 40 | $41,577 |
| JanuviaSitagliptin Phosphate | 22 | $35,460 |
| TrulicityDulaglutide | 31 | $22,955 |
| MounjaroTirzepatide | 18 | $21,684 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,284 |
| FarxigaDapagliflozin Propanediol | 17 | $14,997 |
| EpogenEpoetin Alfa | 11 | $13,353 |
| Atorvastatin Calcium | 646 | $9,745 |
| EntrestoSacubitril/Valsartan | 25 | $8,560 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 24 | $7,539 |
| MyrbetriqMirabegron | 12 | $7,184 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $146,510235 claims |
| Novo NordiskOzempic | $23 | $56,62354 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $93 | $44,63949 claims |
| Boehringer IngelheimJardiance | $14 | $41,57740 claims |
| MerckJanuvia | $65 | $35,46022 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Breo Ellipta | $287 | $34,32774 claims |
| AstraZenecaFarxiga, Symbicort | $558 | $21,94732 claims |
| AmgenEpogen | $47 | $13,35311 claims |
| NovartisEntresto | $68 | $8,56025 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $7,18412 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $47 | $3,96211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Fallbrook
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.